Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

21.91 -0.68 (-3.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition ↗
Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value... 
Via Benzinga
News headline image
Why Pacira Biosciences Stock Sank Today ↗
A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5... 
Via Benzinga
News headline image
Pacira BioSciences, inc (PCRX) Q2 2021 Earnings Call Transcript ↗
PCRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Outlook For Pacira BioSciences ↗
Pacira BioSciences (NASDAQ:PCRX) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2021 ↗
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 ↗
Upgrades Tudor Pickering upgraded the previous rating for Precision Drilling Corp (NYSE: 
Via Benzinga
News headline image
Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries ↗
Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal... 
Via Benzinga
News headline image
Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important ↗
Shares of Heron Therapeutics Inc (NASDAQ: HRTX) are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego,... 
Via Benzinga
News headline image
Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript ↗
PCRX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Earnings Scheduled For May 4, 2021 ↗
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers BioVie (NASDAQ:BIVI) shares rose 11.62% to $24.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 27.3K shares,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 9, 2021 ↗
Upgrades For Assertio Holdings Inc (NASDAQ:ASRT), Gabelli & Co. upgraded the previous rating of Hold to Buy. The current stock performance of Assertio Holdings shows a... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.